Table 3.
Reasons for combining dapagliflozin and sitagliptin
Reason | Number of patients (%) |
---|---|
Uncontrolled glycemia | 151 (89.9) |
Weight gain | 56 (33.3) |
Hypoglycemia due to other GLP-1 analog/insulin/other OADs | 40 (23.8) |
Glycemic variability | 127 (75.6) |
Hospitalization because of cardiovascular disease | 83 (49.4) |
GLP-1, glucagon-like peptide 1; OAD, oral antidiabetic drug.